SCHEMBL4015178

SCHEMBL4015178

CCCC[C@@H](C)[C@@H](C)[C@@H](CC(=O)O)NC(=O)CN

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G2C Q5R387 1/20 0.36
GPR84 Q9NQS5 4/20 0.36
PDF Q9HBH1 1/20 0.35
PLA2G10 O15496 3/20 0.34
DPP7 Q9UHL4 3/20 0.34
DPP8 Q6V1X1 2/20 0.34
SLC15A1 P46059 1/20 0.33
CTSC P53634 1/20 0.33
DPP4 P27487 2/20 0.33
DPP9 Q86TI2 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CNR2 P34972 1/20 0.33
DNM1 Q05193 1/20 0.33
FAAH O00519 1/20 0.33
MAPK1 P28482 1/20 0.33
MMP1 P03956 1/20 0.32
MMP2 P08253 1/20 0.32
MMP3 P08254 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014957 1.00 PLA2G2C (0.36) PLA2G2CGPR84PDFPLA2G10DPP7
SCHEMBL4009104 1.00 PLA2G2C (0.36) PLA2G2CGPR84PDFPLA2G10DPP7
SCHEMBL4009847 0.91 CTSC (0.35) GPR84PLA2G10CTSC
SCHEMBL4014983 0.91 CTSC (0.35) GPR84PLA2G10CTSC
SCHEMBL4014292 0.91 CTSC (0.35) GPR84PLA2G10CTSC
SCHEMBL4010281 0.86 DPP7 (0.35) PLA2G2CGPR84PDFPLA2G10DPP7
SCHEMBL4014232 0.85 PLA2G2C (0.38) PLA2G2CGPR84PDFPLA2G10DPP7
SCHEMBL4014195 0.84 CTSC (0.36) CTSC
SCHEMBL4005337 0.84 CTSC (0.36) CTSC
SCHEMBL4008007 0.84 CTSC (0.36) CTSC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US claimed
EP-1670750-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN Warner-Lambert Company LLC (US) 2006-06-21 EP claimed
WO-2005030703-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2005-04-07 WO claimed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US claimed
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US disclosed
EP-1670750-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN Warner-Lambert Company LLC (US) 2006-06-21 EP disclosed
WO-2005030703-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2005-04-07 WO disclosed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein SCN2A, OPRD1, SCN1A PLA2G2C 1607/4885GPR84 1293/4885PDF 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.